Bharat Biotech seeks DCGI approval for phase 2/3 Covaxin booster trial among two to 18-year-old

New Delhi, May 4: Bharat Biotech has sought permission from India’s drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI. Presently, precaution

Source: India News, India Breaking News, Latest news headlines in India – Oneindia News